



Stem Cell  
Network

Réseau de  
Cellules Souches


Powering Regenerative Medicine  
Propulsons la médecine régénératrice

# ONTARIO BY THE NUMBERS

## SCN REGIONAL PROFILE

For nearly 25 years, the Stem Cell Network (SCN) has led the way in building national capacity in stem cell and regenerative medicine by supporting world-class research and empowering leading researchers and trainees from coast to coast.

Stem cell and regenerative medicine researchers in **Ontario** are making important advancements in areas such as, muscular dystrophy, lung disease, cardiac disease and multiple sclerosis.



## FUNDS INVESTED IN ONTARIO RESEARCH

# \$26,523,449

# 77

TOTAL PROJECTS  
FUNDED

# 10

CLINICAL  
TRIALS FUNDED

# 87

INVESTIGATORS  
SUPPORTED

# 12

INSTITUTIONS  
SUPPORTED

## MATCHING FUNDS FROM PARTNERS

# \$31,348,453

# 1,226

TRAINEES  
SUPPORTED

*Data from 2016 onward*

## DISEASES OR ILLNESS AREAS SUPPORTED



SEPSIS



MULTIPLE SCLEROSIS



LUNG DISEASE



OSTEOARTHRITIS



CARDIAC DISEASE



CANCER



MUSCULAR DYSTROPHY

WATCH US IN ACTION



STEMCELLNETWORK.CA



# RESETTING THE BODY'S SELF-REPAIR SYSTEM TO TREAT DEVASTATING MUSCLE DISORDERS: SATELLOS BIOSCIENCE INC.

Muscular dystrophy is the term used to cover the 160 known neuromuscular disorders, with the following six being the most common: Duchenne muscular dystrophy (DMD), spinal muscular atrophy, myotonic dystrophy, facioscapulohumeral muscular dystrophy, Charcot-Marie-Tooth disease, and myasthenia gravis.

Collectively, neuromuscular disorders impact more than [50,000 Canadians](#), costing the Canadian economy an average of [\\$4.6 billion annually](#). DMD is caused by an absence of the protein dystrophin that supports the integrity of muscle cells, affecting 1 in every 3,500 male births worldwide.

[Satellos Bioscience Inc.](#) is a publicly traded, clinical-stage biotechnology company advancing novel therapeutics to restore natural muscle repair and regeneration in people living with degenerative muscle diseases. Co-founded by Frank Gleeson and Dr. Michael Rudnicki in partnership with Bloom Burton & Co. — Canada's leading healthcare investment firm — Satellos is built upon foundational research from the Rudnicki lab, funded by the Stem Cell Network. Satellos is leveraging its proprietary MyoReGenX™ discovery platform, built on breakthrough insights into muscle stem cell polarity, to identify diseases where impaired stem cell division limits muscle regeneration. This platform is enabling the development of first-in-class treatments that directly address underlying deficiencies in the muscle repair process.

The company's lead program, SAT-3247, is a first-in-class, orally administered small molecule drug currently in clinical development for Duchenne muscular dystrophy (DMD). SAT-3247 targets the AAK1 protein, identified by Satellos as a critical regulator that mimics the repair signal normally provided by dystrophin in healthy muscle. By restoring this signal, SAT-3247 supports proper muscle stem cell division and promotes natural repair and regeneration of muscle tissue. In addition to DMD, Satellos is investigating broader applications of its platform in other muscle disorders and injury-related conditions where enhancing the body's regenerative capacity could provide therapeutic benefit. Satellos is headquartered in Toronto, Ontario.

**From 2016 to 2029, SCN has committed over \$4.8 million in funding for innovative muscular dystrophy research, \$2 million of which directly supported research used to inform the groundbreaking work happening at Satellos.**

For more information, visit [www.satellos.com](http://www.satellos.com)



**FOUNDED: 2018**

**# OF EMPLOYEES: ~25**


**LOCATION: Toronto, ON**

**MOST RECENT INVESTMENT:  
US\$40M or CA\$57M  
gross process following  
equity offering**

**“Duchenne muscular  
dystrophy is a  
devastating disease,  
but stem cell research is  
providing new hope.”**

**Dr. Michael Rudnicki**

Senior Scientist and Scientific  
Director, Regenerative Medicine,  
The Ottawa Hospital  
Professor, University of Ottawa  
Chief Scientific Officer, Satellos



**Stem Cell  
Network**

Powering  
Regenerative  
Medicine

**Réseau de  
Cellules Souches**

Propulsons  
la médecine  
régénératrice

The Stem Cell Network (SCN) is a national not-for-profit that funds stem cell and regenerative medicine (RM) research; trains the next generation of talent; enables knowledge mobilization of research; and enhances the commercialization readiness of stem cell and RM innovations. From the lab to the clinic, the SCN community is connected by a common vision: to transform lives through regenerative medicine.

**STEMCELLNETWORK.CA** [f](#) [t](#) [@](#) [in](#) [v](#)